gipa69
collegio dei patafisici
smile ha scritto:ritento lungo di bund(10yr)114,95
e sono corto da stamani sull exx
penso sia arrivato il momento di ritestare i minimi dell 14/06 x l'equity
mentre il bund dovrebbe spingersi sino a 116,5 piu' di 1 figura e mezza
ora non ci resta che attendere .
gli stop sono x il bund 114,7 x lo stock 3600 .
il ciclo dei mkt e le loro correlazioni dovrebbero essere queste
con le mp forti
Andrea posta spesso quelle chartsono davvero
Direi che in linea di massima la vedo anche io così... o almeno diciamo che è il mio scenario preferito
Stock futures slip amid rate jitters
By Ellis Mnyandu
NEW YORK (Reuters) - U.S. stock futures slipped on Tuesday, suggesting a flat to lower open, as caution ahead of the Federal Reserve's policy-setting meeting kept most investors on the sidelines.
Comments by European Central Bank's Governing Council member Nicholas Garnagas, saying in a Bloomberg report that the ECB stood ready to quicken the pace of interest rate hikes, also added to the market's jitters.
ADVERTISEMENT
The Fed's policy-setting committee is expected to lift its benchmark lending rate to 5.25 percent after a two-day meeting on Thursday and may give an indication of future rate policy at meetings in August and September. Higher rates are seen as a negative for stocks because they cut into consumers' disposable income and raise costs for businesses.
"Today is a wait-and-see day. There's not a lot that's going to move the needle in the early going," said Arthur Hogan, chief market analyst at Jefferies & Co. in Boston.
"You are going to be hard-pressed to find somebody making a large bet in front of Thursday's Fed's announcement."
S&P 500 futures fell 2.30 points, a shade below fair value, a mathematical formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract.
Dow Jones industrial average futures were down 22 points, and Nasdaq 100 futures fell 1.75 points.
Investors would also keep an eye on the start of confirmation hearings by the Senate Finance Committee for Goldman Sachs Chairman Henry Paulson, who was recently nominated to be Treasury Secretary.
Genentech Inc. will be in the spotlight after the company said it halted the clinical trial of cancer drug Avastin in combination with chemotherapy as a first-line treatment for advanced pancreatic cancer.
In other drug sector news, U.S. generic drug maker Barr Pharmaceuticals has won the battle for Croatia's Pliva with a $2.2 billion cash offer.
Elsewhere, French telecoms and media group Vivendi on Tuesday said it has sold its 1.8 percent stake in chemical company DuPont for $671 million.. DuPont shares were down 1.8 percent in Europe.
On the earnings front, only Nike Inc. , the world's largest athletic footwear and clothing maker, is scheduled to report fiscal fourth-quarter results.
On Monday, U.S. stocks rose amid a flurry of mergers and acquisition deals. The Dow Jones industrial average shot up 56.19 points, or 0.51 percent, to end at 11,045.28. The Standard & Poor's 500 Index gained 6.06 points, or 0.49 percent, to finish at 1,250.56 and returned to positive territory for the year.
The Nasdaq Composite Index rose 12.20 points, or 0.58 percent, to close at 2,133.67.
